HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Estee Lauder projections

This article was originally published in The Rose Sheet

Executive Summary

Sales for fiscal fourth quarter (ended June 30) expected to increase approximately 7% in constant currency versus year-ago period, and sales for the year expected to be up 3%, Estee Lauder announces July 2. Company previously predicted sales for the year would increase 1%-2%. Earnings per share forecast at $.18 and $1.10 for the quarter and year, respectively, before restructuring charges. The estimate is below previous predictions due to increased spending on advertising and promotions, Estee Lauder says. Company anticipates that $77 mil. after-tax charge associated with Internet, supply chain, globalization and distribution will yield annual savings of $43 mil. (1"The Rose Sheet" May 6, 2002, p. 6)...

Sales for fiscal fourth quarter (ended June 30) expected to increase approximately 7% in constant currency versus year-ago period, and sales for the year expected to be up 3%, Estee Lauder announces July 2. Company previously predicted sales for the year would increase 1%-2%. Earnings per share forecast at $.18 and $1.10 for the quarter and year, respectively, before restructuring charges. The estimate is below previous predictions due to increased spending on advertising and promotions, Estee Lauder says. Company anticipates that $77 mil. after-tax charge associated with Internet, supply chain, globalization and distribution will yield annual savings of $43 mil. (1 , p. 6)....

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel